ATE364628T1 - METHODS AND COMPOSITIONS FOR DIAGNOSING TUMORS - Google Patents

METHODS AND COMPOSITIONS FOR DIAGNOSING TUMORS

Info

Publication number
ATE364628T1
ATE364628T1 AT05018355T AT05018355T ATE364628T1 AT E364628 T1 ATE364628 T1 AT E364628T1 AT 05018355 T AT05018355 T AT 05018355T AT 05018355 T AT05018355 T AT 05018355T AT E364628 T1 ATE364628 T1 AT E364628T1
Authority
AT
Austria
Prior art keywords
polypeptides
present
methods
treatment
diagnosis
Prior art date
Application number
AT05018355T
Other languages
German (de)
Inventor
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Kenneth J Hillan
Scot A Masters
James Pan
Robert M Pitti
Margaret Ann Roy
Victoria Smith
Donna M Stone
Colin K Watanabe
William I Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/en
Priority claimed from PCT/US1999/028634 external-priority patent/WO2000036102A2/en
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE364628T1 publication Critical patent/ATE364628T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)

Abstract

The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as predictors of the prognosis of tumor treatment. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
AT05018355T 1999-03-08 2000-02-11 METHODS AND COMPOSITIONS FOR DIAGNOSING TUMORS ATE364628T1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US12397299P 1999-03-11 1999-03-11
US13345999P 1999-05-11 1999-05-11
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14065099P 1999-06-22 1999-06-22
US14065399P 1999-06-22 1999-06-22
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
US14622299P 1999-07-28 1999-07-28
US14939599P 1999-08-17 1999-08-17
US15168999P 1999-08-31 1999-08-31
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/028301 WO2000032776A2 (en) 1998-12-01 1999-12-01 Secreted amd transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/028634 WO2000036102A2 (en) 1998-12-16 1999-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
ATE364628T1 true ATE364628T1 (en) 2007-07-15

Family

ID=27578504

Family Applications (6)

Application Number Title Priority Date Filing Date
AT05018354T ATE363489T1 (en) 1999-03-08 2000-02-11 GENE SEQUENCES REPLICATED IN TUMORS AND THEIR DIAGNOSTIC USES
AT05018353T ATE422536T1 (en) 1999-03-08 2000-02-11 COMPOSITIONS AND METHODS FOR DIAGNOSIS OF TUMORS
AT05018355T ATE364628T1 (en) 1999-03-08 2000-02-11 METHODS AND COMPOSITIONS FOR DIAGNOSING TUMORS
AT05018357T ATE377025T1 (en) 1999-03-08 2000-02-11 COMPOSITIONS AND METHODS FOR DIAGNOSING TUMORS
AT05018358T ATE380195T1 (en) 1999-03-08 2000-02-11 COMPOSITIONS AND METHODS FOR TREATING TUMORS
AT05018356T ATE348108T1 (en) 1999-03-08 2000-02-11 METHOD FOR DETECTING TUMORS

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT05018354T ATE363489T1 (en) 1999-03-08 2000-02-11 GENE SEQUENCES REPLICATED IN TUMORS AND THEIR DIAGNOSTIC USES
AT05018353T ATE422536T1 (en) 1999-03-08 2000-02-11 COMPOSITIONS AND METHODS FOR DIAGNOSIS OF TUMORS

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT05018357T ATE377025T1 (en) 1999-03-08 2000-02-11 COMPOSITIONS AND METHODS FOR DIAGNOSING TUMORS
AT05018358T ATE380195T1 (en) 1999-03-08 2000-02-11 COMPOSITIONS AND METHODS FOR TREATING TUMORS
AT05018356T ATE348108T1 (en) 1999-03-08 2000-02-11 METHOD FOR DETECTING TUMORS

Country Status (10)

Country Link
EP (7) EP1626058B1 (en)
JP (6) JP2004520003A (en)
KR (1) KR100512819B1 (en)
AT (6) ATE363489T1 (en)
AU (3) AU2003200722B2 (en)
CA (5) CA2479476C (en)
DK (5) DK1626058T3 (en)
ES (6) ES2296029T3 (en)
PT (5) PT1626058E (en)
WO (1) WO2001053486A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US7160679B1 (en) 1998-05-21 2007-01-09 Diadexus, Inc. Method of diagnosing, monitoring, and staging lung cancer
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
CA2348757A1 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA01007163A (en) 1999-01-15 2002-03-27 Biogen Inc Antagonists of tweak and of tweak receptor and their use to treat immunological disorders.
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2002045570A2 (en) * 2000-12-07 2002-06-13 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of viral disease using 55092
FR2843395A1 (en) * 2002-08-12 2004-02-13 Genfit S A New synthetic peptide from apolipoprotein AIV related protein, useful for raising antibodies, used for diagnosis and treatment of disorders of lipid metabolism
IL160531A0 (en) * 2001-09-07 2004-07-25 Genfit Compositions and methods for aa4rp assay
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003072773A1 (en) * 2002-02-08 2003-09-04 Seikagaku Corporation Fused protein having glucuronyl transferase activity
CA2462133A1 (en) 2002-02-20 2003-08-28 Kunitake Abe Novel polypeptide
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
MX352180B (en) 2002-04-09 2017-11-13 Biogen Ma Inc Methods for treating tweak-related conditions.
EP1572952B1 (en) * 2002-06-28 2010-09-29 Imclone LLC Novel polynucleotide and polypeptide sequences and uses thereof
CA2489515C (en) * 2002-06-29 2013-01-22 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
WO2004015079A2 (en) * 2002-08-07 2004-02-19 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2005028633A2 (en) 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of rankl expression
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
LT1781698T (en) 2004-07-20 2016-09-26 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
CA2577690C (en) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
EP1853312B1 (en) * 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
WO2009002193A1 (en) * 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
JP3399948B2 (en) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Method for detecting precancerous cells or cancer cells using P90 antibody or probe
EP0679716A4 (en) * 1993-11-12 1999-06-09 Kenichi Matsubara Gene signature.
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
JP2001512013A (en) * 1997-08-01 2001-08-21 ジェンセット 5'EST of secreted protein expressed in prostate
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
CA2319129A1 (en) * 1998-01-30 1999-08-05 Human Genome Sciences, Inc. 67 human secreted proteins
IL138216A0 (en) * 1998-03-02 2001-10-31 Millennium Pharm Inc Novel fdrg protein and nucleic acid molecules and uses therefor
DE19818620A1 (en) * 1998-04-21 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New polypeptides and their nucleic acids, useful for treatment of bladder tumor and identification of therapeutic agents
EP1105474A2 (en) * 1998-05-14 2001-06-13 Chiron Corporation Human genes and gene expression products v
CA2331154A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2000004135A2 (en) * 1998-07-16 2000-01-27 Incyte Pharmaceuticals, Inc. Human scad-related molecules, scrm-1 and scrm-2
WO2000006728A2 (en) * 1998-07-28 2000-02-10 Incyte Pharmaceuticals, Inc. Phosphorylation effectors
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
WO2001053455A2 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2353797A1 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
CA2390438A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 19 human secreted proteins
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
EP1623990A2 (en) 2006-02-08
CA2479511A1 (en) 2001-07-26
EP1623989B1 (en) 2007-06-13
KR20010103045A (en) 2001-11-17
EP1173563A1 (en) 2002-01-23
PT1607402E (en) 2007-03-30
DK1632499T3 (en) 2007-10-01
ATE380195T1 (en) 2007-12-15
JP2004520003A (en) 2004-07-08
AU2003200722C1 (en) 2003-05-01
PT1626058E (en) 2008-02-15
EP1632499B9 (en) 2008-02-20
CA2479494C (en) 2010-02-02
EP1626084B1 (en) 2009-02-11
JP2004201654A (en) 2004-07-22
CA2479476C (en) 2009-11-10
EP1626058B1 (en) 2007-10-31
ES2296029T3 (en) 2008-04-16
KR100512819B1 (en) 2005-09-07
AU2003200731C1 (en) 2008-07-17
ATE377025T1 (en) 2007-11-15
CA2479498A1 (en) 2001-07-26
DK1623989T3 (en) 2007-10-15
ES2279473T3 (en) 2007-08-16
EP1632499A2 (en) 2006-03-08
JP2004229503A (en) 2004-08-19
CA2479494A1 (en) 2001-07-26
EP1607402A1 (en) 2005-12-21
EP1623990B1 (en) 2007-12-05
JP2004229504A (en) 2004-08-19
EP1626084A1 (en) 2006-02-15
ES2290834T3 (en) 2008-02-16
ES2321954T3 (en) 2009-06-15
EP1626058A1 (en) 2006-02-15
CA2365610A1 (en) 2001-07-26
EP1623989A1 (en) 2006-02-08
DK1623990T3 (en) 2008-04-07
JP2004201652A (en) 2004-07-22
EP1632499B1 (en) 2007-05-30
AU2003200722B2 (en) 2006-02-02
EP1632499A3 (en) 2006-03-15
AU2003200731B2 (en) 2006-04-13
PT1632499E (en) 2007-09-11
ATE363489T1 (en) 2007-06-15
DK1626058T3 (en) 2008-02-25
WO2001053486A1 (en) 2001-07-26
EP1623990A3 (en) 2006-03-01
DK1607402T3 (en) 2007-04-16
AU2003200740C1 (en) 2008-07-17
EP1607402B1 (en) 2006-12-13
ES2289630T3 (en) 2008-02-01
ES2298896T3 (en) 2008-05-16
PT1623990E (en) 2008-03-18
ATE348108T1 (en) 2007-01-15
AU2003200740B2 (en) 2005-12-15
CA2479476A1 (en) 2001-07-26
JP2004201653A (en) 2004-07-22
PT1623989E (en) 2007-09-25
ATE422536T1 (en) 2009-02-15

Similar Documents

Publication Publication Date Title
ATE377025T1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING TUMORS
DE60042799D1 (en) Methods for the diagnosis of tumors
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
DE69839571D1 (en) Fibroblast growth factor-19
ATE432987T1 (en) METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH
ATE357518T1 (en) METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH
DE69941273D1 (en) Compilation and method for the diagnosis of tumors
WO2000037640A3 (en) Compositions and methods for the treatment of tumor
EP1820860A3 (en) Methods and compositions for inhibiting neoplastic cell growth

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1623989

Country of ref document: EP

REN Ceased due to non-payment of the annual fee